Several patients with Aids got bone marrow transplants and all traces of the virus disappeared. Yahoo won't let you publish a link, but it was on Motley Fool. Could that have hurt GILD stock price? It makes a lot of money from HIV treatment.
. . . of greater potential concern for GILD's HIV franchise, I think, are genetic therapies that are currently being developed and tested . . . one in particular has shown some promise as a "functional cure" . . . and, if successful, it would likely cost considerably less than $200K . . .